Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02972424 · ClinicalTrials.gov registry record · Phase 2
PTH(1-34) and Pelvic Fracture Healing - a Randomized Controlled Trial
A Phase 2 study, sponsored by Hospital for Special Surgery, New York.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT02972424 is a Phase 2 study that has completed, run by Hospital for Special Surgery, New York. The registered enrollment target is 35 participants.
The verdict
NCT02972424, a Phase 2 study, has completed, sponsored by Hospital for Special Surgery, New York.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
In the proposed trial the investigators will recruit women and men \>65 years of age with acute osteoporosis-related pelvic fractures and address 3 specific aims over 3 months of treatment in a placebo controlled double blind study to determine if standard care and teriparatide 20 mcg/day versus placebo for pelvic fractures: 1. Results in earlier evidence of cortical bridging on routine radiographs followed by confirmatory Focus CT, a novel method to reduce radiation exposure from CT scans (primary outcome). 2. Leads to a faster reduction in pain as assessed by both the Numeric Rating Scale and a reduction in the use of narcotics (secondary outcome). 3. Leads more rapidly to improved functional outcome using a short physical performance battery to assess lower extremity function (secondary outcome).
Interventions
- DRUG Placebo
- DRUG Teriparatide Prefilled Syringe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2021-07-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02972424
The ClinicalTrials.gov registry entry for NCT02972424 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hospital for Special Surgery, New York, which has 194 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02972424 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02972424 about?
NCT02972424 is a clinical study titled "PTH(1-34) and Pelvic Fracture Healing - a Randomized Controlled Trial". In the proposed trial the investigators will recruit women and men \>65 years of age with acute osteoporosis-related pelvic fractures and address 3 specific aims over 3 months of treatment in a placebo controlled double blind study to determine if standard care and teriparatide 20 mcg/day versus pla...
What is the current status of trial NCT02972424?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2017-05-01. Estimated completion is 2021-07-08.
What interventions are being tested in trial NCT02972424?
The interventions under investigation include: Placebo (DRUG), Teriparatide Prefilled Syringe (DRUG).
Who is sponsoring clinical trial NCT02972424?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.